Literature DB >> 8093870

Bleeding duodenal ulcer. Role of gastric acid hypersecretion.

M J Collen1, A N Kalloo, M J Sheridan.   

Abstract

Basal gastric acid output was analyzed prospectively in 110 patients with endoscopically documented duodenal ulcer disease to determine the frequency of gastric acid hypersecretion in patients with bleeding versus nonbleeding ulcers. Thirty-eight patients with stigmata of an actively or recently bleeding duodenal ulcer had a mean basal output of 12.6 +/- 8.9 meq/hr. In comparison, 72 patients with nonbleeding duodenal ulcers (and no history of prior bleeding) had a significantly lower mean basal acid output of 8.7 +/- 7.5 meq/hr (P < 0.05). Twenty-four of the 38 patients (63%) with bleeding and 28 of the 72 (39%) with nonbleeding duodenal ulcers had gastric acid hypersecretion, defined as a basal acid output of greater than 10.0 meq/hr. There was a statistically significant association between bleeding duodenal ulcer and acid hypersecretion (P = 0.01). All 110 patients were treated with standard doses of H2-receptor antagonists for eight weeks. In that time, 87 patients healed and 23 patients (14 with prior bleeding and nine with nonbleeding duodenal ulcers) remained unhealed. Significantly more patients who had bled had nonhealing duodenal ulcers (P = 0.004). Irrespective of bleeding history, all 23 patients with nonhealing duodenal ulcers at eight weeks had basal acid outputs of greater than 10.0 meq/hr (range 10.1-49.1 meq/hr). These 23 patients with nonhealing duodenal ulcers were treated with increased doses of ranitidine (mean 690 mg/day, range 600-1200 mg/day) for up to eight additional weeks. All were observed to have complete endoscopic healing documented within that period.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8093870     DOI: 10.1007/bf01307543

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  33 in total

1.  Healing of duodenal ulcer with an antacid regimen.

Authors:  W L Peterson; R A Sturdevant; H D Frankl; C T Richardson; J I Isenberg; J D Elashoff; J Q Sones; R A Gross; R W McCallum; J S Fordtran
Journal:  N Engl J Med       Date:  1977-08-18       Impact factor: 91.245

2.  Refractory duodenal ulcers (nonhealing duodenal ulcers with standard doses of antisecretory medication).

Authors:  M J Collen; V J Stanczak; C A Ciarleglio
Journal:  Dig Dis Sci       Date:  1989-02       Impact factor: 3.199

3.  Reliability of symptoms in assessing control of gastric acid secretion in patients with Zollinger-Ellison syndrome.

Authors:  J P Raufman; S M Collins; S J Pandol; L Y Korman; M J Collen; M J Cornelius; M K Feld; D M McCarthy; J D Gardner; R T Jensen
Journal:  Gastroenterology       Date:  1983-01       Impact factor: 22.682

4.  Effect of no treatment, cimetidine 1 g/day, cimetidine 2 g/day and cimetidine combined with atropine on nocturnal gastric secretion in cimetidine non-responders.

Authors:  T Gledhill; M Buck; R H Hunt
Journal:  Gut       Date:  1984-11       Impact factor: 23.059

5.  The national ASGE survey on upper gastrointestinal bleeding. II. Clinical prognostic factors.

Authors:  F E Silverstein; D A Gilbert; F J Tedesco; N K Buenger; J Persing
Journal:  Gastrointest Endosc       Date:  1981-05       Impact factor: 9.427

6.  Famotidine therapy for active duodenal ulcers. A multivariate analysis of factors affecting early healing.

Authors:  J C Reynolds
Journal:  Ann Intern Med       Date:  1989-07-01       Impact factor: 25.391

7.  Cimetidine treatment of duodenal ulceration: short term clinical trial and maintenance study.

Authors:  D J Hetzel; P J Hansky; D J Shearman; M G Korman; R Hecker; G J Taggart; R Jackson; B W Gabb
Journal:  Gastroenterology       Date:  1978-02       Impact factor: 22.682

Review 8.  Zollinger-Ellison syndrome. Current concepts in diagnosis and management.

Authors:  M M Wolfe; R T Jensen
Journal:  N Engl J Med       Date:  1987-11-05       Impact factor: 91.245

9.  Very long-term treatment of peptic ulcer with cimetidine.

Authors:  J M Cargill; J H Saunders; N Peden; K G Wormsley
Journal:  Lancet       Date:  1978-11-25       Impact factor: 79.321

10.  Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome.

Authors:  J M Howard; A N Chremos; M J Collen; K E McArthur; J A Cherner; P N Maton; C A Ciarleglio; M J Cornelius; J D Gardner; R T Jensen
Journal:  Gastroenterology       Date:  1985-04       Impact factor: 22.682

View more
  3 in total

1.  Idiopathic gastric acid hypersecretion. Comparison with Zollinger-Ellison syndrome.

Authors:  M J Collen; R T Jensen
Journal:  Dig Dis Sci       Date:  1994-07       Impact factor: 3.199

2.  Ranitidine therapy in patients with idiopathic gastric acid hypersecretion. A prospective study.

Authors:  M J Collen; J F Wirshup
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

3.  Giant duodenal ulcer. Evaluation of basal acid output, nonsteroidal antiinflammatory drug use, and ulcer complications.

Authors:  M J Collen; M J Santoro; Y K Chen
Journal:  Dig Dis Sci       Date:  1994-05       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.